Eye Cancer Recurrence: What to Ask

This is the hardest fact on the page, and the most useful. NCI reports that spread from uveal melanoma travels through the bloodstream, and that the liver is usually the first place found.

In the COMS trials, the liver was the only site of spread in 46 percent of people who developed metastases. Another 43 percent had the liver plus other sites. Lung, bone and tissue under the skin are also common.

That is why liver surveillance is a large part of follow-up, even when the eye itself looks settled. It does not replace the eye examinations. Both run in parallel, and your ocular oncology team sets the pattern for each.

NCI's pathology checklist for uveal melanoma includes a gene expression profile reported as class 1 or class 2. It also includes chromosome status: loss on chromosome 3, gain on 6p, gain on 8q.

These describe risk. They do not decide treatment on their own. Ask which of them was done on your tumor and what the report said.

Yes, though it is less common than spread. NCI's health-professional summary cites a randomized single-centre comparison in which local tumour regrowth occurred in 13.3 percent of the plaque brachytherapy arm, against 0 percent in the helium ion arm. That is one study, not a COMS result, and it is not a figure to read as your own risk.

Ask how your eye will be checked: examination, photographs, or ultrasound of the eye. Ask how often, and for how long.

The NCI patient summary cited below still says, of both recurrent and metastatic disease, that "an effective treatment for metastatic intraocular melanoma has not been found," and points to clinical trials.

That sentence has not kept up. NCI's own drug pages list tebentafusp-tebn as approved for uveal melanoma that cannot be removed by surgery or has spread. It is used in adults who carry the HLA-A*02:01 antigen, which is checked with a blood test.

We are flagging the disagreement rather than choosing between the two pages. Ask your specialist about it directly.

This is a different disease with different follow-up. New tumors in the eye are found on examinations, and NCI notes that in young children a dilated eye exam "may be done under anesthesia."

NCI's retinoblastoma summary describes frequent, regular eye examinations for heritable disease, continuing for a long stretch after treatment. The team sets the interval. It varies with the child's age, genes and findings. Work from the schedule you were given, not from a general figure. After an eye is removed, "close follow-up is needed for 2 years or more to check for signs of recurrence in the area around the affected eye and to check the other eye." NCI adds that exams of the unaffected eye continue until the retinoblastoma is known to be the non-heritable form.

Ask how often those examinations are needed for your child, when they stop, and whether both eyes are being checked.

• How will my liver be checked, how often, and for how long?
• Are blood tests enough, or do I need imaging as well?
• What did my class and chromosome results show?
• Does that change how closely I am watched?
• How will you check whether the tumor regrew in my eye?
• Am I HLA-A*02:01 positive, and does tebentafusp apply to me?
• Which trial should I be looking at now?

Ask for the schedule in writing. Ask who to call between visits.

• Call 911 or go to an emergency department if you are on tebentafusp and get a fever with dizziness, light-headedness, or fainting, or with wheezing or trouble breathing. That combination can mean cytokine release syndrome, which the drug's label warns can be life-threatening. Your infusion centre should have given you a written toxicity plan and a number to ring. Use both. Tell whoever sees you which drug you are on.
• Call your care team the same day if your vision changes suddenly, you get new floaters or flashes of light, your eye becomes painful or red, or the pupil or the position of the eyeball changes. For a child treated for retinoblastoma, call the same day for a white pupil in flash photos, eyes that start to look crossed, redness, or an eye that looks larger than before.
• Call your care team within a day or two if your skin or the whites of your eyes turn yellow, you get new pain under the right ribs, or you lose weight without trying. Uveal melanoma spreads to the liver most often.

Cancer Staging and Biomarker Testing explain the terms that come up most when eye cancer comes back. Clinical Trial vs Standard Treatment, Palliative Care, and Questions to Ask Your Doctor cover the decisions that follow an eye cancer recurrence.

These questions were drawn from current patient guidance for eye cancer (uveal melanoma; retinoblastoma in children):

• NCI PDQ — Intraocular (Uveal) Melanoma Treatment (Patient Version)
• NCI PDQ — Intraocular (Uveal) Melanoma Treatment (Health Professional Version)
• NCI — Tebentafusp-tebn
• NCI PDQ — Retinoblastoma Treatment (Patient Version)
• DailyMed — KIMMTRAK (tebentafusp-tebn) label, boxed warning on cytokine release syndrome